Cancer research, Rhabdomyosarcoma, Pharmacology, Cell biology and PI3K/AKT/mTOR pathway are his primary areas of study. Peter J. Houghton interconnects Growth factor receptor, Methyltransferase, Immunology and Protein kinase A in the investigation of issues within Cancer research. His Rhabdomyosarcoma research is multidisciplinary, incorporating elements of Internal medicine, Chemotherapy and Neuroblastoma.
His Pharmacology research is multidisciplinary, incorporating perspectives in Camptothecin, Irinotecan, Transplantation and In vivo. As a part of the same scientific study, he usually deals with the In vivo, concentrating on In vitro and frequently concerns with Osteosarcoma and Distribution. His research in Cell biology intersects with topics in Cell cycle, Transcription factor and Cell culture.
Peter J. Houghton focuses on Cancer research, In vivo, Pharmacology, Rhabdomyosarcoma and Internal medicine. Within one scientific family, Peter J. Houghton focuses on topics pertaining to PI3K/AKT/mTOR pathway under Cancer research, and may sometimes address concerns connected to Cell growth and Phosphorylation. Peter J. Houghton focuses mostly in the field of In vivo, narrowing it down to topics relating to Cell culture and, in certain cases, Molecular biology.
Peter J. Houghton works mostly in the field of Pharmacology, limiting it down to topics relating to Irinotecan and, in certain cases, Camptothecin, as a part of the same area of interest. His research in Rhabdomyosarcoma tackles topics such as Vincristine which are related to areas like Melphalan. His Internal medicine research incorporates themes from Endocrinology and Oncology.
His main research concerns Cancer research, Cancer, In vivo, Internal medicine and Sarcoma. Particularly relevant to Osteosarcoma is his body of work in Cancer research. His In vivo study also includes
His work in the fields of Internal medicine, such as Leukemia, Toxicity and Novel agents, overlaps with other areas such as Preclinical testing. When carried out as part of a general Sarcoma research project, his work on Rhabdomyosarcoma is frequently linked to work in Eribulin, therefore connecting diverse disciplines of study. While the research belongs to areas of Cell culture, he spends his time largely on the problem of Cell growth, intersecting his research to questions surrounding PI3K/AKT/mTOR pathway and Transcription factor.
Peter J. Houghton mainly focuses on Cancer research, In vivo, Internal medicine, Pharmacology and Sarcoma. His work carried out in the field of Cancer research brings together such families of science as Cancer and Leukemia, Immunology. His In vivo research integrates issues from IC50, In vitro, Vincristine, Downregulation and upregulation and Wilms' tumor.
In his study, Tumor xenograft, Potency and Docetaxel is strongly linked to Oncology, which falls under the umbrella field of Internal medicine. His research in Pharmacology is mostly focused on Pharmacokinetics. The Rhabdomyosarcoma research Peter J. Houghton does as part of his general Sarcoma study is frequently linked to other disciplines of science, such as Eribulin, therefore creating a link between diverse domains of science.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The tor pathway: a target for cancer therapy
Mary-Ann Bjornsti;Peter J. Houghton.
Nature Reviews Cancer (2004)
Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin
Gregory J. Brunn;Christine C. Hudson;Aleksandar Sekulić;Josie M. Williams.
mTOR and cancer therapy.
J B Easton;P J Houghton.
Targeting mTOR signaling for cancer therapy.
Shile Huang;Peter J Houghton.
Current Opinion in Pharmacology (2003)
Methods to Detect P-Glycoprotein-associated Multidrug Resistance in Patients' Tumors: Consensus Recommendations
William T. Beck;Thomas M. Grogan;Cheryl L. Willman;Carlos Cordon-Cardo.
Cancer Research (1996)
Establishment of human tumor xenografts in immunodeficient mice.
Christopher L Morton;Peter J Houghton.
Nature Protocols (2007)
The pediatric preclinical testing program: description of models and early testing results.
Peter J. Houghton;Christopher L. Morton;Chandra Tucker;Debbie Payne.
Pediatric Blood & Cancer (2007)
Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors
Peter J. Houghton;Pamela J. Cheshire;James D. Hallman;Lois Lutz.
Cancer Chemotherapy and Pharmacology (1995)
Irinotecan Therapy in Adults With Recurrent or Progressive Malignant Glioma
Henry S. Friedman;William P. Petros;Allan H. Friedman;Larry J. Schaaf.
Journal of Clinical Oncology (1999)
Rapamycins: mechanism of action and cellular resistance.
Shile Huang;Mary Ann Bjornsti;Peter J. Houghton.
Cancer Biology & Therapy (2003)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: